Related Experiment Video
Updated: Aug 5, 2026
08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
Tofacitinib in uveitis and scleritis
Parthopratim Dutta Majumder1, Fathima Fahima1, Rakshita Deepak Kene1
1Department of Uvea and Intraocular Inflammation, Sankara Nethralaya, Chennai, Tamil Nadu, India.
Oman Journal of Ophthalmology
|July 28, 2026
Summary
Tofacitinib, a Janus kinase (JAK) inhibitor, shows promise for treating refractory ocular inflammation like uveitis and scleritis. While effective, its use requires careful consideration of potential cardiovascular, thromboembolic, and infectious side effects.
Area of Science:
- Ophthalmology
- Immunology
- Pharmacology
Background:
- Janus kinases (JAKs) are key in inflammatory signaling pathways.
- JAK inhibitors represent a therapeutic strategy for inflammatory diseases.
- Ophthalmology is exploring JAK inhibitors for conditions like uveitis and scleritis.
Purpose of the Study:
- To review the clinical efficacy and safety of tofacitinib in ocular inflammation.
- To highlight tofacitinib's role in managing refractory uveitis and scleritis.
- To discuss the emerging literature on tofacitinib's risks and side effects in ophthalmology.
Main Methods:
- Literature review of studies on tofacitinib for ocular inflammation.
- Analysis of clinical efficacy data in uveitis and scleritis.
- Evaluation of safety profiles and adverse events reported for tofacitinib.
Main Results:
- Tofacitinib demonstrates effectiveness in managing refractory uveitis and scleritis, often when conventional therapies fail.
- Its oral formulation and distinct inhibition profile offer therapeutic advantages.
- Adverse events, including cardiovascular risks, thromboembolism, infections, and malignancies, require monitoring.
Conclusions:
- Tofacitinib is a potential therapeutic option for recalcitrant ocular inflammatory conditions.
- Balancing efficacy with a thorough understanding of its safety profile is crucial for clinical application.
- Further research is needed to fully elucidate tofacitinib's long-term impact in ophthalmology.
Related Concept Videos
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:29Inflammatory Bowel Disease IV: Pharmacological Management
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
01:16TGF - β Signaling Pathway
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors are of three kinds RI, RII, and RIII. The RI...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms: